Q4 2024 Compugen Ltd Earnings Call Transcript
Key Points
- Compugen Ltd (CGEN) presented encouraging data for COM701, showing durable responses and good tolerability in platinum-resistant ovarian cancer patients.
- The company plans to advance COM701 as a maintenance treatment for platinum-sensitive ovarian cancer, targeting a less competitive landscape.
- AstraZeneca's initiation of seven Phase 3 trials with rilvegostomig, derived from Compugen's COM902, represents a significant potential revenue source.
- Compugen Ltd (CGEN) received a $30 million milestone payment from Gilead for GS-0321's FDA IND clearance, validating their discovery and development capabilities.
- The company maintains a solid financial position with a cash runway expected to last into 2027, supporting their strategic priorities and clinical advancements.
- Compugen Ltd (CGEN) reported a net loss of approximately $14.2 million for the year ended December 31, 2024.
- Revenues for 2024 decreased compared to 2023, with $27.9 million reported versus $33.5 million in the previous year.
- The TIGIT antibody class faced skepticism due to several setbacks and program discontinuations in 2024.
- The ovarian cancer study is exploratory and not powered to detect significant improvements, which may limit its impact.
- There is uncertainty regarding the timeline and outcomes of AstraZeneca's Phase 3 trials, which could affect future revenue streams.
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's fourth-quarter and full-year 2024 results conference call. (Operator instructions)
An audio webcast of this call is available in the Investors section of Compugen's website www.cgen.com. As a reminder, today's call is being recorded. I would now like to introduce Yvonne Naughton, Vice President, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.
Thank you, operator, and thank you all for joining us on the call today. Joining me from Compugen for the prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer, and David Silberman, Chief Financial Officer. Dr. Michelle Mahler, Chief Medical Officer, and Dr. Eran Ophir, Chief Scientific Officer, will join us for the Q&A.
Before we begin, we would like to remind you that during this call, the company may make projections
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
